The secret to turning our body's own soldiers into super-killers of cancer is finally being unlocked! Imagine your immune system's elite warriors, the CD8 killer T cells, as highly trained operatives. Scientists have just discovered the genetic blueprints that dictate whether these cells become long-lasting, vigilant defenders or weary, ineffective troops when fighting cancer. This breakthrough could revolutionize how we design these powerful cells for therapy.
At UT Southwestern Medical Center, researchers found that by boosting a protein called BACH2, they could make engineered cancer-fighting immune cells act more like stem cells. Think of stem cells as the ultimate versatile recruits, capable of replenishing and adapting. This means these CAR T cells (chimeric antigen receptor T cells) become more potent and effective in their therapeutic mission. This offers exciting new avenues for enhancing the power of these cellular therapies.
But here's where it gets a bit mysterious: scientists have also identified a previously unrecognized pathway that might explain a stubborn problem in prostate cancer. Even when patients undergo androgen deprivation therapy, which aims to cut off the fuel for this cancer, it often persists and progresses. This new discovery could finally shed light on why and how this happens, opening doors to better treatment strategies.
On the regulatory front, good news! The European Commission has given the green light to Breyanzi (lisocabtagene maraleucel; liso-cel). This is a CD19-directed CAR T cell therapy approved for adult patients battling relapsed or refractory mantle cell lymphoma, especially those who haven't responded to at least two prior systemic therapies, including a Bruton’s tyrosine kinase inhibitor. This marks a significant advancement for patients with this specific type of lymphoma.
In the fight against cancer disparities, the National Cancer Institute (NCI) has awarded a substantial five-year, $11.2 million grant to the University of North Carolina Lineberger Comprehensive Cancer Center. This funding is dedicated to a Specialized Program of Research Excellence focused on Endometrial Cancer Health Disparities, led by Victoria Bae-Jump and Hazel Nichols. It's a crucial step towards ensuring equitable care and research for all.
And this is the part that offers hope for solid tumors: researchers at the USC Norris Comprehensive Cancer Center have demonstrated, using cell cultures and animal models, that next-generation CAR T cells can indeed safely and effectively shrink solid tumors. This has been a major hurdle in CAR T cell therapy, as these cells have historically struggled to penetrate and eliminate solid masses.
Looking back, it's inspiring to see how far we've come. Nearly five decades ago, a pioneering bone marrow transplant (BMT) program was established at City of Hope, with the primary goal of improving outcomes for patients suffering from advanced leukemia. This foundational work paved the way for many of the advanced therapies we see today.
What do you think? Is it ethical to engineer our immune cells to be so aggressive, or is this the necessary next step in conquering cancer? Let us know your thoughts in the comments below!
